BioSpace News Archive

CRH Medical Corporation, announces that it completed an accretive transaction whereby the Company has acquired a 51% interest in FDHS Anesthesia, LLC, a gastroenterology anesthesia practice located in Sarasota, Florida.

DeltaTrak® announces customized vaccine temperature monitoring solutions compatible with the three temperature profiles required for transport, storage and handling of COVID-19 vaccines.

Agilent Technologies Inc. (NYSE: A) today announced that both the NanoDis System and the innovative new style polychromator in the 5800 and 5900 ICP-OES have received Innovation Awards from The Analytical Scientist.

This is one of the first studies to examine how psilocybin affects the immune system and is a required step to file an application with the Food and Drug Administration (FDA), for a Phase 1 clinical study in humans

Eureka Therapeutics, Inc. announced today successful preclinical results from its InvisiMask™ Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, announced that the Company’s management will present at the PNC Bank & Solebury Trout COVID Webinar and LD Micro Investor Conference on December 15, 2020.

Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular diseases, today announced the initiation of a preclinical proof of concept study for OP-801 imaging of neuroinflammation.

The current public health crisis has changed nearly every facet of our lives, but perhaps no shift has been more profound than how we have adapted to work, when required to be around others.

As the world confronts a viral pandemic not seen in the past 100 years, the reverberations are being felt across every sector, from healthcare to the economy, education, business and science, including the blood cancer community.

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the “Agreement”) with Epps Investments LLC (“Epps”). Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later than December 31, 2020 , in exchange for 100% of the payments or other property or va